Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms
99
TL;DR: Data show that subinhibitory concentrations of azithromycin have antibiofilm properties, provide mechanistic insights, and supply an additional rationale for the use of azathromycin in chronic biofilm infections involving H. influenzae.
read more
Abstract: Nontypeable Haemophilus influenzae (NTHi) commonly causes otitis media, chronic bronchitis in emphysema, and early airway infections in cystic fibrosis. Long-term, low-dose azithromycin has been shown to improve clinical outcomes in chronic lung diseases, although the mechanism of action remains unclear. The inhibition of bacterial biofilms by azithromycin has been postulated to be one mechanism mediating these effects. We hypothesized that subinhibitory concentrations of azithromycin would affect NTHi biofilm formation. Laboratory strains of NTHi expressing green fluorescent protein and azithromycin-resistant clinical isolates were grown in flow-cell and static-culture biofilm models. Using a range of concentrations of azithromycin and gentamicin, we measured the degree to which these antibiotics inhibited biofilm formation and persistence. Large biofilms formed over 2 to 4 days in a flow cell, displaying complex structures, including towers and channels. Subinhibitory concentrations of azithromycin significantly decreased biomass and maximal thickness in both forming and established NTHi biofilms. In contrast, subinhibitory concentrations of gentamicin had no effect on biofilm formation. Furthermore, established NTHi biofilms became resistant to gentamicin at concentrations far above the MIC. Biofilm formation of highly resistant clinical NTHi isolates (azithromycin MIC of > 64 microg/ml) was similarly decreased at subinhibitory azithromycin concentrations. Clinically obtainable azithromycin concentrations inhibited biofilms in all but the most highly resistant isolates. These data show that subinhibitory concentrations of azithromycin have antibiofilm properties, provide mechanistic insights, and supply an additional rationale for the use of azithromycin in chronic biofilm infections involving H. influenzae.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Emerging drugs for bronchiectasis.
TL;DR: A concerted, global effort to coordinate studies of both the pathophysiology and potential treatments of bronchiectasis, in its many forms, could lead to substantial improvements in outcomes.
24
Biofilms in pediatric respiratory and related infections.
TL;DR: Understanding the nature of biofilms in common pediatric infections is essential to comprehending the expected course of bacterial illness and identifying treatments that are most likely to be beneficial against more resistant biofilmms.
21
AzaSite® inhibits Staphylococcus aureus and coagulase-negative Staphylococcus biofilm formation in vitro.
Eric C. Wu,Regis P. Kowalski,Eric G. Romanowski,Francis S. Mah,Y. Jerold Gordon,Robert M. Q. Shanks +5 more
TL;DR: The data indicate that AZM has a moderate inhibitory effect onBiofilm formation, whereas DuraSite appears to play a greater role in the inhibition of staphylococcal biofilm formation by AzaSite®.
Haemophilus influenzae responds to glucocorticoids used in asthma therapy by modulation of biofilm formation and antibiotic resistance
Chris Earl,Teh Wooi Keong,Shi-Qi An,Sarah Murdoch,Yvonne McCarthy,Junkal Garmendia,Joseph Ward,J. Maxwell Dow,Liang Yang,George A. O'Toole,Robert P. Ryan +10 more
TL;DR: In this article, the authors show that glucocorticosteroids have a direct influence on the behavior of H.influenzae that may account for associated difficulties with therapy.
The extracellular innate-immune effector HMGB1 limits pathogenic bacterial biofilm proliferation.
Aishwarya Devaraj,Laura A. Novotny,Frank Robledo-Avila,John R. Buzzo,Lauren Mashburn-Warren,Joseph A. Jurcisek,Natalia O. Tjokro,Santiago Partida-Sanchez,Santiago Partida-Sanchez,Lauren O. Bakaletz,Lauren O. Bakaletz,Steven D. Goodman,Steven D. Goodman +12 more
TL;DR: In this paper, the authors describe an extracellular function of the vertebrate highmobility group box 1 protein (HMGB1) in the proliferation of bacterial biofilms.
References
Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis
George A. O'Toole,Roberto Kolter +1 more
TL;DR: The genetic analyses suggest that biofilm formation can proceed via multiple, convergent signalling pathways, which are regulated by various environmental signals, and that of the 24 sad mutants analysed in this study, only three had defects in genes of known function.
2.6K
Quantification of biofilm structures by the novel computer program COMSTAT.
Arne Heydorn,Alex Toftgaard Nielsen,Morten Hentzer,Claus Sternberg,Michael Givskov,Bjarne Kjær Ersbøll,Søren Molin +6 more
TL;DR: Analysis of biofilms of P. aureofaciens growing on 0.03 mM, 0.1 mM or 0.5 mM citrate minimal media showed that mean biofilm thickness increased with increasing citrate concentration, whereas surface to volume ratio increased with higher citrate concentrations.
2.1K
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.
TL;DR: The association between an exacerbation and the isolation of a new strain of a bacterial pathogen supports the causative role of bacteria in exacerbations of chronic obstructive pulmonary disease.
1.1K
•Book
Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments : United States, 1996
Schappert Sm
- 01 Jun 1997
TL;DR: Utilization varied by patient age, sex, and race; Persons 75 years and over had the highest rate of ambulatory care visits; and Females had significantly higher rates of visits to physician offices and hospital outpatient departments than males did.
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Lisa Saiman,Bruce C. Marshall,Bruce C. Marshall,Nicole Mayer-Hamblett,Jane L. Burns,Alexandra L. Quittner,Debra A. Cibene,Sarah Coquillette,Ann Yunker Fieberg,Frank J. Accurso,Preston W. Campbell +10 more
TL;DR: Azithromycin treatment was associated with improvement in clinically relevant end points and should be considered for patients with CF who are 6 years or older and chronically infected with P aeruginosa.
994
Related Papers (5)
Luanne Hall-Stoodley,Fen Z. Hu,Fen Z. Hu,Armin Gieseke,Armin Gieseke,Laura Nistico,Duc Nguyen,Jay Hayes,Michael L. Forbes,David P. Greenberg,Bethany Dice,Amy Burrows,P. Ashley Wackym,Paul Stoodley,Paul Stoodley,J. Christopher Post,J. Christopher Post,Garth D. Ehrlich,Garth D. Ehrlich,Joseph E. Kerschner +19 more